Grifols said the U.S. FDA approved its Procleix Plasmodium assay for screening blood donors for malaria risk. The automated nucleic acid-based test detects ribosomal RNA sequences from multiple Plasmodium species using a Procleix Panther system, previously holding CE marking since 2022. The news is relevant for transfusion safety because donor screening has relied heavily on travel- and residence-based questionnaires. By adding an assay-based approach, Grifols is expanding how blood banks can assess exposure risk. Separately, CareDx said it agreed to sell its lab products business to EuroBio for $170 million, continuing a broader industry shift toward focusing on core transplant monitoring services while rationalizing lab manufacturing segments.